Cycle on Jun 17, 2026

I will begin by listing the open threads and watches for the topic to see if there are any specific questions or catalysts we need to follow up on.

I will perform a web search to identify the most recent and consequential science and health news from the last week, specifically looking for major clinical trial readouts, FDA approvals, disease outbreaks, or space breakthroughs.

The search results include some social media posts and general articles, but let's do a more targeted search for specific biotech, pharma, space, and infectious disease news over the last week. I'll search for specific FDA approvals or major trial data in June 2026. Let's do a search for "FDA approval" with freshness "week" and "clinical trial" with freshness "week".

Wow, this is an excellent set of leads! Let's look at several of these: 1. **FDA Approves New Indication for Tzield (teplizumab) for recently diagnosed Stage 3 Type 1 Diabetes**. (Wait, our list of threads has a watch for Tzield: `Sanofi Tzield Phase 3 BETA-PRESERVE confirmatory trial in Stage 3 T1D` (id: `019ec32d-357a-793f-b934-70957f5a30f5`). Let's search and fetch details on this Tzield FDA approval! This is huge. It says: "FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes. First disease modifying..."). Let's search for this FDA approval specifically. 2. **belzutifan with pembrolizumab (Welireg + Keytruda)**: "On June 12, 2026, the Food and Drug Administration approved... belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma." Let's fetch details on this. 3. **capivasertib with abiraterone and prednisone (Truqap)**: "FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer." Wait, is this AstraZeneca's "Key Prostate Cancer FDA Approval" on June 15, 2026? Yes! Let's search and fetch details. 4. **uniQure's AMT-130**: "After FDA demands full trial for AMT-130, uniQure pivots to UK regulatory pathway with Q3 2026 filing planned." This sounds like a major development in gene therapy! Let's look into this. 5. **Phase 3 EMNERGIZE Trial Launches to Evaluate Empasiprubart in CIDP**: Wait, CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) is a major focus in our watches (e.g. Sanofi's riliprubart, Dianthus's claseprubart). Let's see if this is related or a new competitor. Let's do targeted web searches on these topics. First, let's search for Sanofi's Tzield FDA approval for recently diagnosed Stage 3 Type 1 Diabetes. Let's see when it happened and what trial it's based on. Is it PROTECT Phase 3? Let's check.

Let's fetch the Sanofi press release on Tzield or the Breakthrough T1D article to get the exact quotes, details of the PROTECT Phase 3 trial, dosage, indication, and the confirmatory trial (BETA-PRESERVE). This is a critical regulatory milestone. Let's start with `web_fetch` on `https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-12-22-09-58-3311349` or the Breakthrough T1D URL. Let's try the Sanofi press release first.

This is fantastic! The FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) on June 12, 2026, for children aged 8 to 17 recently diagnosed with Stage 3 T1D (to delay decline in endogenous insulin production). This is based on the Phase 3 PROTECT study (NCT03875729). And the confirmatory trial is Phase 3 BETA-PRESERVE (NCT07088068), which is currently enrolling. Let's see if we have a watch for this. Yes! Watch ID: `019ec32d-357a-793f-b934-70957f5a30f5` is `Sanofi Tzield Phase 3 BETA-PRESERVE confirmatory trial in Stage 3 T1D` with description "Monitor the Phase 3 BETA-PRESERVE (NCT07088068) confirmatory study for Sanofi's Tzield (teplizumab-mzwv) in newly diagnosed Stage 3 Type 1 diabetes to verify clinical benefit following its accelerated approval." Wait, this watch is actually tracking the results / readout of the confirmatory trial (BETA-PRESERVE) to verify benefit, which is expected to fire when Sanofi reports topline safety and efficacy results from the Phase 3 BETA-PRESERVE trial (fire date: Dec 31, 2028). So this watch does NOT resolve yet, as BETA-PRESERVE is still enrolling. But we have a major update on the regulatory status of Tzield in Stage 3 T1D, which we should write a finding for! Wait, let's look at other major news from our search: 1. **uniQure's AMT-130**: "After FDA demands full trial for AMT-130, uniQure pivots to UK regulatory pathway with Q3 2026 filing planned." Let's search for this to find out more. Is it a gene therapy for Huntington's disease? Let's check. 2. **belzutifan with pembrolizumab (Welireg + Keytruda)**: Adjuvant treatment of renal cell carcinoma. Approved on June 12, 2026. 3. **capivasertib with abiraterone and prednisone (Truqap)**: "FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer." Let's check this. 4. **Empasiprubart Phase 3 EMNERGIZE Trial Launches in CIDP**: This is very interesting. Let's research this. 5. **Amgen's Tavneos FDA hearing submission and public docket close** (Watch ID: `019ec855-5381-7936-a3b6-a40d207e679d`). The trigger is "Fires when Amgen submits its evidence and the public docket closes on June 29, 2026." Since today is June 17, 2026, has Amgen made any submissions or are there updates? Let's search. 6. **Belite Bio tinlarebant NDA completed**: "Belite Bio completes rolling NDA submission of oral tinlarebant for Stargardt". We have a prior finding `belite-bio-tinlarebant-stargardt-disease-nda` and a watch `019ec855-8c35-71a4-b33b-90db344bf45d` which is "Monitor the FDA's decision to accept Belite Bio's NDA for tinlarebant in Stargardt disease type 1 following the 60-day filing review period, and the assignment of a PDUFA target action date (expected around early August 2026, 60 days post-submission)." Since the submission was completed on June 12, 2026, the 60-day review period is ongoing. Let's see if there are any updates on this. First, let's search for "uniQure" and "AMT-130" to see what happened.

Wait, this is an interesting contrast! One article from a non-standard domain (`eciks.org`) says: "After FDA demands full trial for AMT-130, uniQure pivots to UK regulatory pathway with Q3 2026 filing planned" (which seems to be an old or AI-generated hallucination or misinterpretation of something from May 2026, or a scraper gone wrong). But the real, massive news today (June 17, 2026) is: "FDA says 3-year Phase I/II AMT-130 data can support an accelerated-approval BLA. uniQure now targets a Q3 2026 filing and plans a confirmatory study design..." "uniQure stock surged 67.5% in pre-open trading after the company announced that the FDA, following a recent Type B meeting..." "uniQure announces plan for BLA submission for AMT-130 in Huntington's disease" Let's fetch the actual press release or the Stock Titan 8-K filing details on this. This is a massive, highly consequential development in gene therapy and Huntington's disease! This would be the first ever accelerated approval path for a Huntington's disease treatment! Let's use `web_fetch` on `https://www.stocktitan.net/news/QURE/uni-qure-announces-plan-for-bla-submission-for-amt-130-in-huntington-jh4bm1tmrf3p.html` or another reliable article to read the full details. Let's try fetching the Stock Titan press release first.

Let's also search for the actual press release text to get verbatim quotes directly from uniQure or the FDA regarding this decision. Let's do a search for "uniQure" "AMT-130" "BLA" "Q3 2026" "June 17, 2026".

This is an amazing story of a regulatory U-turn! I should fetch the GlobalNewswire page at `https://www.globenewswire.com/news-release/2026/06/17/3313322/0/en/uniqure-announces-plan-for-bla-submission-for-amt-130-in-huntington-s-disease.html` to get the actual quotes from uniQure management and the details of the agreement. Let's do that.

This is a massive story! Let's analyze what changed: - In March 2026, the FDA told uniQure that external-control Phase I/II AMT-130 data were insufficient for filing and pushed for a sham-controlled study. uniQure's stock crashed by 32.8% on March 2, 2026. - In June 2026 (specifically June 17, 2026), following a recent Type B meeting, the FDA did a major U-turn: they agreed that the ~3-year analysis from the Phase I/II study of AMT-130 is acceptable as the primary basis for a BLA for accelerated approval! - uniQure plans to submit the BLA in Q3 2026. - The FDA is seeking to align on the confirmatory study design *prior* to the BLA submission, including considering concurrent control on standard-of-care therapy instead of a sham-procedure. The FDA said they will work as expeditiously as possible. - This represents the first potential accelerated approval path for Huntington's disease, and an incredible regulatory shift. - This deserves a high-profile note! Let's coin a stable slug like `uniqure-amt-130-huntington-disease-fda-path`. Wait, let's look at other stories: 1. **belzutifan with pembrolizumab (Welireg + Keytruda)**: Adjuvant treatment of renal cell carcinoma. Let's search for details on this. "On June 12, 2026, the Food and Drug Administration approved belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma." Let's check the details of this FDA approval. Is it based on a specific trial? Let's check. 2. **capivasertib with abiraterone and prednisone (Truqap)**: "FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer." Wait, let's search for this as well. 3. **Phase 3 EMNERGIZE Trial Launches to Evaluate Empasiprubart in CIDP**: Let's see: empasiprubart is a complement C2 inhibitor. This is very relevant to our watches on CIDP (riliprubart, claseprubart). Let's search for "EMNERGIZE" "empasiprubart" "CIDP" to see who is sponsor and what the trial details are. Is it Annexon? Let's check. 4. Let's check if there are any updates on **Amgen's Tavneos FDA hearing submission and public docket close** (Watch ID: `019ec855-5381-7936-a3b6-a40d207e679d`). The fire date is June 29, 2026. Has anything been submitted yet or are there any news updates? Let's search. 5. Let's check if there are any updates on **Belite Bio tinlarebant NDA completed**. The submission was completed on June 12, 2026. Let's run a web search for the belzutifan + pembrolizumab approval.

Let's fetch the Merck press release or the Dana-Farber study page (`https://bioengineer.org/dana-farber-study-backs-fda-approval-of-pembrolizumab-belzutifan-combo-for-high-risk-clear-cell-kidney-cancer-post-surgery/` or Merck's news page) to get exact quotes, figures (like Hazard Ratio, Disease-Free Survival, etc.) and details of the Phase 3 LITESPARK-022 trial. This is a very significant oncology approval: the first combination regimen to outperform an active control/monotherapy (Keytruda monotherapy was the standard of care for adjuvant RCC) or to show improved results in this setting. Let's look at `https://bioengineer.org/dana-farber-study-backs-fda-approval-of-pembrolizumab-belzutifan-combo-for-high-risk-clear-cell-kidney-cancer-post-surgery/` or the Merck website. Let's do a search for Merck's press release or fetch details. Let's try fetching the Dana-Farber study page first.

This is a very powerful, detailed article. Key details: - FDA approved pembrolizumab (Keytruda) + belzutifan (Welireg) on June 12, 2026. - Indication: Adjuvant treatment for adult patients with clear cell renal cell carcinoma (ccRCC) who face intermediate-high or high risk of disease recurrence following surgical nephrectomy (with or without metastatic lesion removal). - Based on the Phase 3 LITESPARK-022 clinical trial, led by Dr. Toni Choueiri of Dana-Farber. - Enrollment: 1,841 patients who underwent nephrectomy and had no residual disease but high estimated risk of relapse. - Randomization: pembrolizumab + belzutifan vs. pembrolizumab + placebo. - Results: 28% reduction in the risk of recurrence, metastasis, or death (Hazard Ratio = 0.72? Let's check). - At 2 years, ~81% of patients in the combo arm remained free from cancer vs. 74% in the pembrolizumab monotherapy arm. - It also includes the subcutaneous formulation of pembrolizumab (Keytruda Qlex). Let's write a finding for this. The slug can be `fda-approves-belzutifan-pembrolizumab-adjuvant-rcc`. Wait, let's also research: 1. **capivasertib with abiraterone and prednisone (Truqap)**: "FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer." Let's search for details on this. Is it based on a specific trial? Let's search "capivasertib" "abiraterone" "prostate cancer" FDA approval June 2026. This was mentioned as happening around June 15, 2026. Let's run a search.

This is another major oncology approval! Let's fetch the AstraZeneca press release (`https://www.astrazeneca.com/media-centre/press-releases/2026/truqap-approved-in-us-for-prostate-cancer.html`) to get exact details like trial name (CAPItello-281), hazard ratio, endpoints, and patient population. This is highly specific and interesting. Let's fetch it.

This is an excellent, detailed press release! Let's analyze it: - **FDA Approved**: June 12, 2026. - **Drug**: Truqap (capivasertib) in combination with abiraterone and prednisone (and androgen deprivation therapy - ADT). - **Indication**: Adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC). - **Trial**: CAPItello-281 Phase III trial (published in *Annals of Oncology*). - **Efficacy**: 19% reduction in the risk of radiographic disease progression or death (Hazard Ratio = 0.81; 95% CI: 0.66–0.98; p=0.034). Median rPFS was 33.2 months for the Truqap combination vs 25.7 months for the placebo arm (an improvement of 7.5 months). - **Biomarker**: PTEN deficiency (present in about 1 in 4 patients with this form of prostate cancer, leading to dysregulation of the PI3K/AKT pathway and representing an aggressive form of the disease with poor outcomes). The FDA concurrently approved a companion diagnostic test to detect PTEN deficiency. - **Safety**: Grade 3 or higher adverse events occurred in 67% of patients on Truqap combo, with rash (12.3%) and hyperglycemia (10.3%) most common. Let's write a finding for this oncology milestone. The slug can be `fda-approves-capivasertib-truqap-pten-deficient-prostate-cancer`. Wait, let's also research: 1. **Phase 3 EMNERGIZE Trial Launches to Evaluate Empasiprubart in CIDP**: Let's see: "The phase 3 EMNERGIZE study evaluates whether the complement C2 inhibitor empasiprubart can improve disability and functional outcomes in adults with..." Let's search "EMNERGIZE" "empasiprubart" "CIDP" to see what company is doing this, and what the trial details are. Is it Annexon? Let's check. And how does it relate to our other CIDP watches? Let's do a search.

Wait! This is highly relevant to our CIDP watches! Let's see what is happening here: Argenx is running the Phase 3 EMVIGORATE and EMNERGIZE studies evaluating the complement C2 inhibitor empasiprubart (ARGX-117) in CIDP. Let's read the article from NeurologyLive `https://www.neurologylive.com/view/phase-3-emnergize-trial-launches-evaluate-empasiprubart-cidp` to understand the trial design, mechanism, and how it fits into the competitive landscape, especially given Sanofi's recent trial setbacks (which also fits our watch on Sanofi's riliprubart MOBILIZE/VITALIZE!). Let's fetch `https://www.neurologylive.com/view/phase-3-emnergize-trial-launches-evaluate-empasiprubart-cidp`.

This is a very cool development in the CIDP landscape, especially given our existing watches on CIDP complement inhibitors (riliprubart, claseprubart). Let's see: we have these watches: - `Sanofi riliprubart Phase 3 VITALIZE trial status and readout in CIDP` (id: `019eb3ba-b64e-790a-aea4-d30ce0280105`) - `Dianthus Therapeutics claseprubart Phase 3 CAPTIVATE trial readout in CIDP` (id: `019eb3ba-77c0-7d10-9832-0f5adb6a27b7`) Wait, let's search if there are any updates on Sanofi's riliprubart or Dianthus's claseprubart, or other CIDP trials. The Benzinga article mentions: "Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In... Sanofi cans late-stage study for rare autoimmune disease on underwhelming efficacy". Wait, did Sanofi cancel a trial recently? Let's search! "Sanofi cans late-stage study for rare autoimmune disease on underwhelming efficacy" Let's do a search for "Sanofi" "riliprubart" OR "CIDP" trial cancel June 2026. This is extremely important because we have a watch on Sanofi's riliprubart CIDP studies! Let's search.

Oh wow! This is a massive development that directly impacts our watches! Let's see: On June 10, 2026, Sanofi announced the discontinuation of the Phase 3 MOBILIZE trial of riliprubart (SAR445088) in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) due to insufficient efficacy at an interim analysis. Wait! This is exactly what our watch `Sanofi riliprubart Phase 3 VITALIZE trial status and readout in CIDP` (id: `019eb3ba-b64e-790a-aea4-d30ce0280105`) is tracking, but wait, the watch description is: "Monitor the regulatory/clinical status and readout of Sanofi's Phase 3 VITALIZE study of riliprubart in IVIg-experienced CIDP patients, following the early termination of the refractory MOBILIZE study." Wait, has the MOBILIZE study *already* been terminated? Yes, the watch description says "following the early termination of the refractory MOBILIZE study." Wait, let's check the date of the announcement: June 10, 2026. Wait, let's fetch the Sanofi press release on MOBILIZE to see if they are also terminating VITALIZE, or what exactly is happening with VITALIZE. Let's fetch `https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-10-05-00-00-3309444`.

This is a major update! Let's examine: - On June 10, 2026, Sanofi announced that the Phase 3 MOBILIZE study of riliprubart (SAR445088) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment is being stopped. - This was based on an interim analysis by an independent data monitoring committee, which determined that the study is unlikely to provide sufficient efficacy (futility). No safety signals were identified. - The ongoing VITALIZE Phase 3 study (NCT06290141) in IVIg-treated patients with CIDP "will be evaluated accordingly." - This represents a significant setback for Sanofi's neurology pipeline and the complement-inhibition strategy in treatment-refractory CIDP. - It also caused Dianthus Therapeutics (DNTH) stock to drop over 20% on June 10, 2026, because Dianthus is developing claseprubart (DNTH-103), a classical complement pathway inhibitor (inhibits C1s) in a similar patient cohort. - Let's check our watch for Dianthus's claseprubart: "Dianthus Therapeutics claseprubart Phase 3 CAPTIVATE trial readout in CIDP (id: `019eb3ba-77c0-7d10-9832-0f5adb6a27b7`): Monitor the Phase 3 CAPTIVATE clinical trial readout for Dianthus Therapeutics' claseprubart (DNTH-103) in IVIg-experienced CIDP patients to assess if classical complement pathway inhibition is effective in this distinct cohort." - Let's see if there is any new information or statement from Dianthus following Sanofi's announcement. Let's do a search for "Dianthus Therapeutics" "claseprubart" "Sanofi" June 2026. This would be a highly relevant update. Let's search.

This is a remarkable, fast-moving corporate and clinical drama! Let's see what happened: - On June 10, 2026, Sanofi stops the MOBILIZE Phase 3 trial of its C1s inhibitor riliprubart in treatment-refractory CIDP. - Dianthus Therapeutics (DNTH) stock drops over 20% because they are developing claseprubart (DNTH-103), which is also a C1s inhibitor, for CIDP in Phase 3 (the CAPTIVATE trial). - Just a few days later, on June 12, 2026 (Friday), Dianthus fires back by releasing an update with strong interim Phase 3 CIDP results from CAPTIVATE showing a **75% responder rate** for claseprubart! They also highlight robust Phase 2 gMG (generalized Myasthenia Gravis) data and a $1.2B cash runway. - This results in a massive stock rebound! - Let's fetch the Dianthus 8-K filing or press release details on Stock Titan (`https://www.stocktitan.net/sec-filings/DNTH/8-k-dianthus-therapeutics-inc-de-reports-material-event-f2a42e43224f.html` or similar search) to find out what exactly they reported for claseprubart in CIDP and gMG, and why analysts (like Truist) argue that Dianthus's development strategy is materially different from Sanofi's. Let's do a search or fetch on this. Let's try `web_fetch` on `https://www.stocktitan.net/sec-filings/DNTH/8-k-dianthus-therapeutics-inc-de-reports-material-event-f2a42e43224f.html`.

Ah, yes, my web search budget for this cycle is spent. So I will stop searching and proceed to write up the findings I have gathered. Wait, let's look at the threads/watches to see if I can resolve any. Let's see: 1. **FDA regulatory decision on Zepzelca's second-line SCLC indication** (id: `019ec855-c507-7a87-9478-04ec177c54da`): I did not find any news about Zepzelca in my searches. 2. **FDA filing acceptance and PDUFA date for Belite Bio's tinlarebant** (id: `019ec855-8c35-71a4-b33b-90db344bf45d`): The rolling submission was completed on June 12, 2026. This watch is for the FDA's decision to accept the filing (expected early August 2026). So it is still ongoing. 3. **Amgen Tavneos FDA hearing submission and public docket close** (id: `019ec855-5381-7936-a3b6-a40d207e679d`): This is expected on June 29, 2026. So it is still ongoing. 4. **Sanofi Tzield Phase 3 BETA-PRESERVE confirmatory trial in Stage 3 T1D** (id: `019ec32d-357a-793f-b934-70957f5a30f5`): This watch is tracking the results of the confirmatory trial, which is currently enrolling and expected around Dec 2028. This watch does NOT resolve, but the *regulatory status* of Tzield has been updated. Wait, is there a thread or watch about Tzield's approval? No, only the watch on the BETA-PRESERVE confirmatory trial. So I will keep this watch open. 5. **Dianthus Therapeutics claseprubart Phase 3 CAPTIVATE trial readout in CIDP** (id: `019eb3ba-77c0-7d10-9832-0f5adb6a27b7`): "Monitor the Phase 3 CAPTIVATE clinical trial readout for Dianthus Therapeutics' claseprubart (DNTH-103) in IVIg-experienced CIDP patients to assess if classical complement pathway inhibition is effective in this distinct cohort." Wait! The watch is for the Phase 3 CAPTIVATE clinical trial readout. This cycle, Dianthus reported an interim responder analysis from Part A of the Phase 3 CAPTIVATE trial. They also updated the trial design of Part B (removing the 600mg dose, reducing the patient size from 192 to 128, and expecting Part B top-line guidance by year-end 2026). The actual clinical trial readout (Part B) is still in the future, but this interim analysis is a significant milestone. Does it resolve the watch? No, the watch is for the full Phase 3 CAPTIVATE trial readout. So I will keep this watch open. 6. **Sanofi riliprubart Phase 3 VITALIZE trial status and readout in CIDP** (id: `019eb3ba-b64e-790a-aea4-d30ce0280105`): "Monitor the regulatory/clinical status and readout of Sanofi's Phase 3 VITALIZE study of riliprubart in IVIg-experienced CIDP patients, following the early termination of the refractory MOBILIZE study." Wait! In this cycle, Sanofi announced the early termination of the refractory MOBILIZE study and stated that the continuation of other ongoing studies, including VITALIZE, "will be evaluated accordingly." This is a major update on the status. However, the VITALIZE trial itself has not been officially terminated or read out yet (it is being evaluated). So I will keep this watch open. Wait, let's write down our findings! We have 5 major findings to write up: 1. **Sanofi’s Tzield Approved as First Disease-Modifying Therapy for Recently Diagnosed Stage 3 Type 1 Diabetes** - Slug: `tzield-fda-approval-stage-3-type-1-diabetes` (Wait, let's check if there is an existing slug. Looking at the "Relevant prior findings" block: - `cdc-ends-h5n1-bird-flu-emergency-response` - `amgen-tavneos-fda-scrutiny-withdrawal-dispute` - `disc-medicine-bitopertin-epp-crl-path` - `belite-bio-tinlarebant-stargardt-disease-nda` - `grail-nhs-galleri-mced-trial-results` There is no existing slug for Tzield's new approval, so we can mint a new slug like `tzield-fda-approval-stage-3-type-1-diabetes`.) 2. **uniQure Secures FDA Path for Accelerated Approval of AMT-130 in Huntington's Disease** - Slug: `uniqure-amt-130-huntington-disease-fda-path` (This is a major regulatory pivot that happened on June 17, 2026!) 3. **FDA Approves Pembrolizumab-Belzutifan Combo for High-Risk Kidney Cancer Post-Surgery** - Slug: `fda-approves-belzutifan-pembrolizumab-adjuvant-rcc` (Based on Phase 3 LITESPARK-022, approved June 12, 2026.) 4. **FDA Approves Capivasertib (Truqap) Combo as First Targeted Therapy for PTEN-Deficient Prostate Cancer** - Slug: `fda-approves-capivasertib-truqap-pten-deficient-prostate-cancer` (Based on Phase 3 CAPItello-281, approved June 12, 2026.) 5. **Sanofi Halts Phase 3 Riliprubart CIDP Trial for Futility, Prompting Dianthus to Disclose Strong Claseprubart Interim Data** - Slug: `cidp-complement-inhibitor-race-sanofi-setback-dianthus-rebound` (This is a major clinical and corporate story tracking Sanofi's MOBILIZE failure and Dianthus's CAPTIVATE Part A interim success.) Let's carefully write these notes with high-quality evidence, verbatim quotes, and links. Let's write the Tzield note first. Indication: Children aged 8 to 17 years recently diagnosed with Stage 3 T1D to delay the decline in endogenous insulin production. Trial: Phase 3 PROTECT study (NCT03875729). Endpoint: significantly slowing the decrease in mean C-peptide levels (difference in least-squares means 0.13 pmol/mL; 95% CI: 0.09-0.17; p<0.001). Confirmatory Study: Phase 3 BETA-PRESERVE (NCT07088068). Quotes from Aaron J. Kowalski, Christopher Corsico. Let's call `write_note` for the Tzield approval.

Now I will write the second note regarding uniQure's massive regulatory pivot for AMT-130 in Huntington's Disease. Details: - FDA communicated during a Type B meeting that the 3-year Phase I/II data is acceptable as the primary basis of a BLA for accelerated approval. - BLA submission planned for Q3 2026. - FDA seeks to align on the confirmatory study design *prior* to submission, including concurrent control on standard-of-care instead of a sham procedure. - This is a massive U-turn because in March 2026, the FDA had stated that the external-control Phase I/II data were insufficient, driving a 32.8% stock crash on March 2, 2026. - AMT-130 has RMAT, Breakthrough Therapy, and Fast Track designations. - Let's call `write_note` for uniQure's AMT-130.

Now I will write the third note on the FDA approval of Merck's pembrolizumab-belzutifan combo for high-risk kidney cancer post-surgery. Details: - FDA approved pembrolizumab (Keytruda) + belzutifan (Welireg) on June 12, 2026. - Indication: Adjuvant treatment for adults with clear cell renal cell carcinoma (ccRCC) who face intermediate-high or high risk of disease recurrence following surgical nephrectomy (with or without metastatic lesion removal). - Based on the Phase 3 LITESPARK-022 clinical trial, led by Dr. Toni Choueiri of Dana-Farber. - Results: 28% reduction in the risk of recurrence, metastasis, or death compared to pembrolizumab + placebo (Hazard Ratio = 0.72? Wait, the text says "compelling clinical benefit: patients receiving the combination therapy exhibited a 28% reduction in the risk of recurrence, metastasis, or death compared to those on the control arm."). - At 2 years, ~81% of patients in the combo arm remained free from cancer vs. 74% in the pembrolizumab monotherapy arm. - First combination regimen to outperform pembrolizumab monotherapy (which was the standard of care). - Let's call `write_note` for this kidney cancer approval.

Now I will write the fourth note: the FDA approval of AstraZeneca's Truqap (capivasertib) combination as the first targeted treatment for PTEN-deficient metastatic prostate cancer. Details: - FDA approved Truqap (capivasertib) in combination with abiraterone and prednisone on June 12, 2026. - Indication: Adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC). - Based on Phase 3 CAPItello-281 trial. - Results: 19% reduction in the risk of radiographic disease progression or death (Hazard Ratio = 0.81; 95% CI: 0.66–0.98; p=0.034). Median rPFS was 33.2 months for the Truqap combination vs 25.7 months for the placebo arm (an improvement of 7.5 months). - Represents the first and only targeted treatment option for PTEN-deficient mAPMN/S prostate cancer. - PTEN deficiency represents an aggressive form of the disease associated with poor outcomes (occurs in ~1 in 4 of these patients). - Let's call `write_note` for this prostate cancer approval.

Now I will write the fifth note, which is the major clinical and competitive story tracking the CIDP complement inhibitor race: Sanofi's Phase 3 MOBILIZE failure (riliprubart) and Dianthus's Phase 3 CAPTIVATE Part A interim success (claseprubart). Details: - On June 10, 2026, Sanofi announced that the Phase 3 MOBILIZE study of its C1s inhibitor riliprubart in treatment-refractory CIDP was stopped for futility. - Dianthus Therapeutics (DNTH) stock dropped over 20% on the news due to concerns that complement inhibition is ineffective in CIDP. - On June 11-12, 2026, Dianthus published an updated corporate presentation detailing its Phase 3 CAPTIVATE Part A interim responder analysis: - 75% response rate (30 out of 40 patients) based on adjusted INCAT improvement. - Predefined target was 50% (20 patients), which prompted an early GO decision supported by an independent DSMB. - This strong data caused a massive stock rebound. - Dianthus also detailed differences between CAPTIVATE and other trials (ADHERE, etc.) and head-to-head in vitro potency showing claseprubart is 4x-8x more potent than riliprubart at blocking the classical complement pathway. - Let's call `write_note` for this clinical and competitive story.

This is an incredibly comprehensive set of notes capturing major, highly consequential updates from this week! Let's review if we need to resolve any threads. Wait, let's list our threads again. We have: - `FDA regulatory decision on Zepzelca's second-line SCLC indication` (id: `019ec855-c507-7a87-9478-04ec177c54da`): No updates. - `FDA filing acceptance and PDUFA date for Belite Bio's tinlarebant` (id: `019ec855-8c35-71a4-b33b-90db344bf45d`): No updates yet (expected early August). - `Amgen Tavneos FDA hearing submission and public docket close` (id: `019ec855-5381-7936-a3b6-a40d207e679d`): No updates yet (expected June 29). - `Sanofi Tzield Phase 3 BETA-PRESERVE confirmatory trial in Stage 3 T1D` (id: `019ec32d-357a-793f-b934-70957f5a30f5`): This watch is for the trial results/readout (expected Dec 2028). So it's not resolved. - `Dianthus Therapeutics claseprubart Phase 3 CAPTIVATE trial readout in CIDP` (id: `019eb3ba-77c0-7d10-9832-0f5adb6a27b7`): This is for the Phase 3 CAPTIVATE trial readout. Since the trial is still ongoing (Part B just started with a revised design, expecting top-line guidance by year-end 2026), this watch is not resolved yet. - `Sanofi riliprubart Phase 3 VITALIZE trial status and readout in CIDP` (id: `019eb3ba-b64e-790a-aea4-d30ce0280105`): This watch is for VITALIZE's status and readout. Since VITALIZE is currently "being evaluated" and hasn't read out or been officially terminated, it remains open. Wait, are there any watches we should register based on today's findings? Yes! 1. **uniQure's BLA submission for AMT-130 in Huntington's disease**: We know they plan to submit the BLA in Q3 2026. This is a crucial forward-looking catalyst! Let's register a watch for this. - Cardinality: `one_shot` - Watch type: `dated_catalyst` - Title: `uniQure BLA submission for AMT-130 in Huntington's disease` - Fire Date: `2026-09-30T00:00:00Z` - Description: `Monitor uniQure's formal submission of the BLA for AMT-130 in Huntington's disease, targeted for Q3 2026.` 2. **Dianthus Therapeutics' CAPTIVATE Part B top-line guidance**: Dianthus expects to provide top-line guidance for Part B by year-end 2026. Let's register a watch for this. - Cardinality: `one_shot` - Watch type: `dated_catalyst` - Title: `Dianthus CAPTIVATE Part B top-line guidance in CIDP` - Fire Date: `2026-12-31T00:00:00Z` - Description: `Monitor Dianthus's release of top-line guidance for Part B of the Phase 3 CAPTIVATE trial in CIDP (expected by year-end 2026).` 3. **Dianthus Therapeutics' Phase 2 MoMeNtum top-line data in MMN**: Dianthus expects Phase 2 MoMeNtum top-line data in Q4 2026. Let's register a watch for this. - Cardinality: `one_shot` - Watch type: `dated_catalyst` - Title: `Dianthus MoMeNtum Phase 2 top-line data in MMN` - Fire Date: `2026-12-31T00:00:00Z` - Description: `Monitor Dianthus's release of top-line Phase 2 MoMeNtum data for claseprubart in Multifocal Motor Neuropathy (expected in Q4 2026).` Let's record these watches. This is a very clean way to keep track of these milestones. Let's do that!

Now I will register the watch for Dianthus's CAPTIVATE Part B top-line guidance.

Now I will register the watch for Dianthus's MoMeNtum Phase 2 top-line data in MMN (expected in Q4 2026).

Excellent. I have registered all the forward-looking catalysts that we uncovered this cycle. Now, I will call `finish_cycle` to complete this research cycle. Since I have written 5 highly detailed and substantive findings, I will not pass a `no_findings_reason`.

I have completed this research cycle on topic **019e92c9-9dac-7a47-a1f2-f8f4037c94f9** (Consequential Science and Health). The cycle has been highly productive, yielding five major, newly documented findings and registering three forward-looking watches to track future clinical and regulatory milestones. ### Summary of Key Findings Recorded in This Cycle 1. **Sanofi’s Tzield Approved as First Disease-Modifying Therapy for Recently Diagnosed Stage 3 Type 1 Diabetes** - **Slug:** `tzield-fda-approval-stage-3-type-1-diabetes` - **Summary:** On June 12, 2026, the FDA granted accelerated approval to Sanofi’s Tzield (teplizumab-mzwv) to delay the decline of endogenous insulin production in pediatric patients aged 8 to 17 recently diagnosed with clinical Stage 3 T1D. This is a massive expansion from its previous presymptomatic Stage 2 indication. It is supported by the Phase 3 **PROTECT** trial (NCT03875729), which showed a statistically significant preservation of beta-cell function (assessed by C-peptide levels; $p<0.001$). The ongoing Phase 3 **BETA-PRESERVE** trial (NCT07088068) will serve as the confirmatory study. 2. **uniQure Secures FDA Path for Accelerated Approval of AMT-130 in Huntington's Disease** - **Slug:** `uniqure-amt-130-huntington-disease-fda-path` - **Summary:** Following a recent Type B meeting, the FDA executed a major regulatory U-turn on June 17, 2026, agreeing that the 3-year Phase I/II data for uniQure's gene therapy **AMT-130** is acceptable as the primary basis for a BLA seeking accelerated approval. This is a dramatic reversal from March 2026, when the FDA's rejection of the data package triggered a 32.8% stock crash. uniQure plans to submit the BLA in **Q3 2026** and will align with the FDA on a confirmatory trial design that may use concurrent standard-of-care control instead of a sham procedure. 3. **FDA Approves Pembrolizumab-Belzutifan Combo for High-Risk Kidney Cancer Post-Surgery** - **Slug:** `fda-approves-belzutifan-pembrolizumab-adjuvant-rcc` - **Summary:** On June 12, 2026, the FDA approved Merck's **Keytruda (pembrolizumab)** in combination with **Welireg (belzutifan)** as an adjuvant treatment for clear cell renal cell carcinoma (ccRCC) patients at high risk of recurrence following surgical nephrectomy. This is the first combination regimen to outperform pembrolizumab monotherapy (the previous standard of care) in this setting. Based on the Phase 3 **LITESPARK-022** trial led by Dr. Toni Choueiri, the combo demonstrated a **28% reduction in the risk of recurrence, metastasis, or death** compared to pembrolizumab alone, with 81% of patients recurrence-free at 2 years vs. 74% in the control arm. 4. **FDA Approves Capivasertib (Truqap) Combo as First Targeted Therapy for PTEN-Deficient Prostate Cancer** - **Slug:** `fda-approves-capivasertib-truqap-pten-deficient-prostate-cancer` - **Summary:** On June 12, 2026, the FDA approved AstraZeneca's AKT inhibitor **Truqap (capivasertib)** in combination with abiraterone and prednisone for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer (previously mHSPC). Based on the Phase 3 **CAPItello-281** trial, the combination demonstrated a statistically significant **19% reduction in the risk of radiographic disease progression or death** (HR 0.81; $p=0.034$), improving median rPFS by **7.5 months** (33.2 months vs. 25.7 months). PTEN deficiency affects roughly 25% of these patients and is associated with aggressive disease and poor prognosis. 5. **Sanofi's Riliprubart CIDP Trial Fails for Futility, Triggering Dianthus's Strong Claseprubart Interim Data Release** - **Slug:** `cidp-complement-inhibitor-race-sanofi-setback-dianthus-rebound` - **Summary:** On June 10, 2026, Sanofi announced it was stopping its Phase 3 **MOBILIZE** trial of the C1s inhibitor **riliprubart** in treatment-refractory CIDP due to interim futility. This caused a temporary 20% sell-off in peer company Dianthus Therapeutics. However, on June 11-12, Dianthus rebounded strongly by disclosing positive interim Phase 3 **CAPTIVATE** Part A data for its own C1s inhibitor **claseprubart**, showing a **75% responder rate** (30/40 patients) on adjusted INCAT score vs. a 50% target. Dianthus has optimized its Part B trial design and has a robust $1.2B cash runway. ### Forward-Looking Watches Registered To keep this topic dynamic and ensure that we capture critical next steps, I have registered three new watches: 1. **uniQure BLA submission for AMT-130 in Huntington's disease** (`one_shot`, expected Q3 2026) — to monitor the formal filing of the BLA following the FDA's regulatory U-turn. 2. **Dianthus CAPTIVATE Part B top-line guidance in CIDP** (`one_shot`, expected by Year-End 2026) — to monitor the clinical progress and timeline updates for Part B of the Phase 3 trial. 3. **Dianthus MoMeNtum Phase 2 top-line data in MMN** (`one_shot`, expected Q4 2026) — to monitor the clinical readout of claseprubart in Multifocal Motor Neuropathy, which will further validate the classical complement pathway.